The EPIC-CAD trial, recently published in The New England Journal of Medicine, evaluated the efficacy and safety of edoxaban monotherapy compared to dual antithrombotic therapy in patients with stable coronary artery disease (CAD) and high-risk atrial fibrillation (AF). This open-label, … Read More
edoxaban
NOAH-AFNET 6 Trial: Edoxaban in AHRE
The NOAH-AFNET 6 trial, as outlined in a groundbreaking study from the New England Journal of Medicine in 2023, represents a significant advancement in our understanding of atrial fibrillation management. This study scrutinized the efficacy of edoxaban, a novel oral … Read More